Editorial Board
Liang Chen
Assistant Investigator, NIBS, Beijingï-China · China
Editorial leadership for International Journal of Translational Research
Research interests
- Lung Cancer
- Liver Cancer Are The Two Biggest Threats To Chinese Cancer Patients
- Which Claim Yearly 600
- 000 Lives
- 230
- 000 Lives Respectively In Mainland China. The Ultimate Goal Of Research In Our Laboratory Is To Cure Both Diseases. Specifically
- Research Will Focus On The Following Four Areas: Identifying Key Oncogenes Responsible For Tumorigenesis Of Lung Cancer
- Liver Cancer In Chinese Cancer Patients. It'S Been Shown That Although A Cancer Cell Has Many Genetic
- Epigenetic Alterations
- Survival
- Proliferation Of The Cancer Cell Is Often Severely Affected By Inactivation Of A Single Key Oncogene. One Important Area Of Our Lab Is To Identify Oncogenes Responsible For Driving Tumorigenesis In Chinese Lung Cancer
- Liver Cancer Patients
- Which Is The First Step For Developing Targeting Therapies. Deciphering The Changes Happened To Tumor Suppressor Genes In The Process Of Tumorigenesis. In Parallel To Gain-Of-Function Mutation In Oncogenes
- Deregulation In Tumor Suppressor Genes Plays An Important Role In Tumorigenesis. We Will Use Cellular
- Mouse Models To Study The Genetic
- Epigenetic Changes Happened In Tumor Suppressor Genes During Tumorigenesis. Developing Targeting Therapies Against Lung Cancer
- Liver Cancer. Despite The Multimodality Therapies Against Both Cancers
- The 5 Year Survival Rate Remains Disappointingly Low For Both Lung Cancer
- Liver Cancer. Effective Therapies Are Desperately Needed In Clinic. Both Cellular
- Mouse Models Will Be Utilized To Characterize The Biology Of The Tumor Driven By A Given Oncogene. Based On That Information
- We Will Design
- Run A Preclinical Trial In Mouse Model With Small Chemicals/Antibodies Developed. Identifying Serum Protein Biomarkers For Early Diagnosis Of Lung
- Liver Cancer. The Most Effective Way To Benefit Cancer Patients Is Through Diagnose Cancers At Early Stage When The Tumor Can Be Successfully Treated Or Surgically Removed. With Well-Characterized Mouse Model That Develop Tumors After Activation Of Oncogenic Transgene
- We Will Collect Serum From Mouse With Early Stage Tumors. By Comparing The Serum Samples From Tumor-Bearing Mouse
- Well-Controlled Healthy Siblings Through Mass-Spectrometry
- We Plan To Look For The Protein Biomarkers That Are Selectively Present In The Tumor-Bearing Mouse. The Potential Use Of These Biomarkers Will Then Be Confirmed On The Patients- Sera
Biography
Education:
- 2002- Ph.D. in Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, China
- 1996- B.S. in Biotechnology, Department of Biology, Hangzhou University, Zhejiang, China
Professional Experience:
- 2010 - Assistant Investigator, National Institute of Biological Sciences, Beijing, China.
- 2005-2010 - Postdoctoral Fellowï-Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School.
- 2002- 2005 - Postdoctoral Fellowï-Department of Internal Medicine, Yale University School of Medicine.
Considering IJTR for your work?
This journal is guided by Liang Chen (Assistant Investigator, NIBS, Beijingï-China) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.